Mounjaro misused for weight loss in Japan, contraband pens flooding Brazil. Turns out demand doesn't stop at the pharmacy counter. This is GLP-1 Daily. Smuggled pens, a Lilly pill claim with some missing math, and an insurer asking who pays first. Japan first, and what those reports actually prove. Yun Seulgi, writing in The Asia Business Daily:
According to Kyodo News on the 22nd, there have been 35 reports of suspected adverse effects related to the use of Maunzar for dieting or cosmetic purposes submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan over the past three years.
So, Kyodo's count. Thirty-five suspected adverse-event reports to the PMDA over three years, all tied to Maunzar used for dieting or cosmetic purposes. Hypoglycemia, pancreatitis, ketoacidosis. And in Japan that drug's approved for type 2 diabetes only. Which is tirzepatide, for anyone wondering why the name sounds familiar. And I want to slow this down. A suspected adverse-event report is someone saying 'this happened after that.' Some of these cases have unclear causation, and every symptom on that list is already flagged on the package insert. Thirty-five over three years isn't a new safety signal. Sure, but thirty-five out of how many? Nobody can count the denominator when the drug's getting resold person-to-person on social media. And the person who bought a pen off a stranger isn't the one filing a PMDA report. Fair. So the number's probably low, and it's still weak evidence. Both can be true. What worries me is the setup: cash-pay cosmetic clinics, nobody managing the indication. The Health Ministry already sent clinics a warning back in June, and here we are. Here's Christopher Newton, Marina Cavalari and Abby Pender at InSight Crime:
Weight loss and diabetes medications are now one of the most smuggled contraband products in Brazil. Pharmaceuticals produced in neighboring Paraguay are being stolen and diverted into organized crime-controlled smuggling routes as social media drives spiking demand in Brazil. The amount of contraband weight loss medication seized by Brazil’s Federal Revenue Service (Receita Federal do Brasil – RFB) in the first half of the year was 300% more than all of 2025, according to official data obtained by InSight Crime.
Weight-loss pens are now the sixth most-seized contraband category in Brazil. Six years ago this product basically didn't exist there. The first recorded seizure was only in 2023, right around when Mounjaro got approved. And then January 2026 hits and it goes vertical. Brazil's Federal Revenue Service seized 300 percent more in the first half of this year than in all of 2025. Two million dollars' worth of pens in June alone. Here's the part that should worry anyone who bought one. These get stolen in Paraguay, some in armed robberies on pharmacies and warehouses, then run up the Caipira Route through Paraná to São Paulo. Nobody on that route is checking whether the cold chain held. Right, and the woman in São Paulo injecting it has no way to know either. The article pins the demand on social media, but demand for a legit drug only ends up with smugglers when the legal channel isn't reaching her. Mm, I'd split that a little. Our compounders were licensed pharmacies with inspectors. This is organized crime. Same gap, much worse filler. Much worse filler, sure. Same hole in the wall, though. And after the Japan cases we just hit, off-label and unsupervised is starting to look like the default in some places. Adrian Kessler, writing in Mugglehead:
An estimated one-third of patients newly starting oral GLP-1 drugs are taking Foundayo, Eli Lilly and Company NYSE LLY chief executive Dave Ricks told CNBC on Sept. 21, as the drugmaker broke ground on a Houston manufacturing plant. The US$6.5 billion project is expected to operate by 2030, according to CNBC's account.
One-third of new pill starts. One-third of how many people, over which weeks, counted by whom? Ricks said it to CNBC on the twenty-first, and Lilly's own plant release that same day doesn't repeat it. Which tells you plenty. If that number had cleared legal, it'd be in the release. Company-reported, said on TV, no denominator. That belongs up top. The one-third goes in the footnote. And he says share's growing week over week, with no weekly prescription series behind it. Starts aren't dollars, either. A third of new starts could still be a thin slice of sales next to Novo, who's had a pill approved since 2025. Then the backdrop. A six-point-five-billion-dollar ingredients plant in Houston, operating by 2030. I've wanted a real manufacturing ramp for this oral race, and technically, here it is. It just shows up four years after the market-share brag. Oleksii Zaichenko, writing in Traders Union:
In the episode, Zazzera says GLP-1 therapies have become a driver of pharmacy spending as health insurers continue to balance higher near-term drug costs against the potential for lower overall medical costs in the future. He says utilization of the therapies has significantly accelerated, creating a strategic challenge because pharmacy expenses are immediate and measurable while many expected benefits may not be realized for years.
AM Best's Joseph Zazzera, on a podcast, says GLP-1 pharmacy costs are immediate and measurable, and the benefits might not show up for years. Okay. So which insurer's still holding that member in year four, when the knee replacement and the dialysis bill arrive? Usually not the one that said no. And that exact sentence, immediate costs versus uncertain benefits, is the whole case payers make for leaving prior-auth criteria where they are. AM Best rates insurers' financial strength, so when its director calls GLP-1s a strategic challenge, plans hear a ratings risk. Which is what I'd be watching if I were one of the roughly 700,000 seniors on a temporary Medicare access pathway. 'Temporary' plus 'strategic challenge' is how a pathway quietly closes. Step back and look at today. Off-label use in Japan with no clinician in the loop. A seizure spike on the Paraguay border. A Lilly share number with no denominator, and now insurer math that still books the benefit as a maybe. Demand has gotten ahead of the system that's supposed to pay for it, and when that system stalls, people go find a border. If you're finding GLP-1 Daily useful, please subscribe or leave us a review wherever you're listening. Reviews help other people find the show, and we appreciate you being here.
Links to every story are in the show notes, so take a look at the ones you'd like to dig into. That's GLP-1 Daily for today. Thanks for listening, and we'll catch you on the next episode. This is a Lantern Podcast.